Zanidatamab (zani), a HER2-targeted bispecific antibody, in combination with docetaxel as first-line (1L) therapy for patients (pts) with advanced HER2-positive breast cancer: Preliminary results from a phase 1b/2 study.

Lee, KS[Lee, Keun-Seok]; Wang, XJ[Wang, Xiaojia]; Im, YH[Im, Young Hyuck]; Zeng, XH[Zeng, Xiaohua]; Li, HP[Li, Huiping]; Wang, K[Wang, Kun]; Li, HY[Li, Huiyan]; Zhou, P[Zhou, Ping]; Bao, YY[Bao, Yuanyuan]; Jiang, ZF[Jiang, Zefei]

Detailed Information

Cited 0 time in webofscience

Cited 0 time in scopus

Metadata Downloads

Zanidatamab (zani), a HER2-targeted bispecific antibody, in combination with docetaxel as first-line (1L) therapy for patients (pts) with advanced HER2-positive breast cancer: Preliminary results from a phase 1b/2 study.

Authors: Lee, KS[Lee, Keun-Seok]; Wang, XJ[Wang, Xiaojia]; Im, YH[Im, Young Hyuck]; Zeng, XH[Zeng, Xiaohua]; Li, HP[Li, Huiping]; Wang, K[Wang, Kun]; Li, HY[Li, Huiyan]; Zhou, P[Zhou, Ping]; Bao, YY[Bao, Yuanyuan]; Jiang, ZF[Jiang, Zefei]

Issue Date: 1-Jun-2022

Publisher: LIPPINCOTT WILLIAMS & WILKINS

Citation: JOURNAL OF CLINICAL ONCOLOGY, v.40, no.16

Indexed: SCIE
SCOPUS

Journal Title: JOURNAL OF CLINICAL ONCOLOGY

Volume: 40

Number: 16

URI: https://scholarx.skku.edu/handle/2021.sw.skku/101809

ISSN: 0732-183X

Files in This Item: There are no files associated with this item.

Appears in Collections: Medicine > Department of Medicine > 1. Journal Articles

Show full item record

qrcode

Altmetrics

Total Views & Downloads

STATISTICS: Total View:; Daily View:

RSS_1.0 RSS_2.0 ATOM_1.0

(03063) 25-2, SUNGKYUNKWAN-RO, JONGNO-GU, SEOUL, KOREA samsunglib@skku.edu

Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.

Detailed Information

Altmetrics

Total Views & Downloads

BROWSE